Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$145.85M+222.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Wojczewski
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 4,553
- Beta
- 1.26
- Country
- DE
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.14
Financials
Revenue
$145.85M+222.9%Net Income
$-47.42M-637.5%EBITDA
$-27.13M-327.4%Free Cash Flow
$-119.54M-1756.0%EPS (diluted)
$-0.13-471.4%Shares Outstanding (diluted)
355.53M+34.1%Operating Expenses
$50.37MCash & Debt
$465.59MReturn of Capital
$0.00Revenue by Segment (annual)
$300.0KDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $757.26M | $-99.43M | $-0.28 |
| 2024 | $796.97M | $-196.08M | $-0.56 |
| 2023 | $781.43M | $-83.91M | $-0.23 |
| 2022 | $751.45M | $-175.66M | $-0.49 |
| 2021 | $618.03M | $215.51M | $0.65 |
| 2020 | $500.92M | $6.28M | $0.02 |
| 2019 | $446.44M | $38.16M | $0.13 |
| 2018 | $375.40M | $84.17M | $0.28 |
| 2017 | $257.63M | $24.26M | $0.08 |
| 2016 | $164.51M | $27.53M | $0.10 |
| 2015 | $127.68M | $16.52M | $0.07 |
| 2014 | $89.50M | $-6.98M | $-0.03 |
| 2013 | $85.94M | $-25.43M | $-0.10 |
| 2012 | $87.27M | $2.48M | $0.01 |
Valuation
EVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+85.71%Social Signal Score
Mentions (7)
- Newsgurufocus.com·8d ago·Neutral
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardPR NewswireHAMBURG, Germany, Oct. 15, 2026Will lead Evotec's g
View source ↗ - Newsprnewswire.com·8d ago·Negative
…ry innovation Brings more than 25 years of global experience in pharma, biotechnology and academia HAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to …
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Evotec Announces Chief Scientific Officer Transition Dr. Cord Dohrmann to step down as of September 30, 2026 Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026.
View source ↗ - Newsseekingalpha.com·32d ago·Positive
Evotec: The Market Seems Split On The Company's Prospects, Buy Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. I have withdrawn confidence in management's targets; valuation is now strictly on an as-is basis, with no credit given for future guidance. Despite a strong liquidity position and some commercial momentum, profitability remains elusive, and turnaround timelines have been pushed out.
View source ↗ - Newsprnewswire.com·44d ago·Neutral
…calable model for development and continuous manufacturing for biodefense preparedness SEATTLE and HAMBURG, Germany, Sept. 9, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.
View source ↗ - Newsbusinesswire.com·45d ago·Neutral
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-…
View source ↗ - Newsprnewswire.com·51d ago·Positive
… precision of T cell activation based on multispecific antigen signature HAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors.
View source ↗
Earnings
Thu, Nov 5(in 12 days)
Consensus estimate $-0.29 per share
Typical surprise -74.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.17 vs $-0.05miss
- Wed, May 6$-0.46 vs $-0.15miss
- Wed, Apr 8$0.05 vs $0.21miss
- Wed, Nov 5$-0.14 vs $-0.14miss
- Wed, Aug 13$-0.14 vs $-0.18beat
- Tue, May 6$-0.15 vs $-0.11miss
Estimates and results for EVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EVO officers and directors.
- Bought
- $5k
- Sold
- $5k
3 trades
3 trades
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
- Bank Of America Corp /de/bought
- Bank Of America Corp /de/sold
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EVO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.